In a groundbreaking development, Anavex Life Sciences has released key findings from its ANAVEX2-73-AD-004 trial, which evaluated the efficacy and safety of Anavex’s blarcamesine, an oral medication for the treatment of early Alzheimer’s disease (AD). The Phase IIb/III randomized double-blind, placebo-controlled study enrolled 508 participants across 52 medical research centers in five countries. The trial specifically targeted individuals with early-stage Alzheimer’s disease (Stage 3), marking a significant step forward in addressing this devastating neurodegenerative disorder.
Study Design and Participant Information
The ANAVEX2-73-AD-004 study assessed blarcamesine, an oral small-molecule drug, administered once daily in capsule form, with two dosage groups—30 mg and 50 mg—compared to a placebo group. The trial duration was 48 weeks, and participants were offered the opportunity to enroll in an open-label extension study called ATTENTION-AD, which concluded in June 2024.
A total of 462 participants completed the trial, with a mean age of 73.7 years, and nearly half of the participants were women (48.7%). Blarcamesine works by enhancing autophagy through the activation of the SIGMAR1 receptor, which helps restore cellular homeostasis in early Alzheimer’s disease. The trial’s primary focus was to assess the cognitive and functional outcomes, measured by changes in the ADAS-Cog13 and ADCS-ADL scales, alongside secondary outcomes that included changes in the CDR-SB scale and various biomarkers such as the plasma Aβ42/40 ratio and global brain volume.
Key Outcomes from the Trial
The trial successfully met its co-primary cognitive endpoint, showing a statistically significant improvement in cognitive performance as measured by the ADAS-Cog13 scale, which is one of the most widely used tools for assessing cognitive impairment in Alzheimer’s disease. Blarcamesine demonstrated a difference of -2.027 in ADAS-Cog13 scores compared to placebo (95% CI -3.522 to -0.533; P=0.008). Furthermore, the CDR-SB scale, which assesses clinical dementia, also showed significant improvement in the blarcamesine group, with a difference of -0.483 (95% CI -0.853 to -0.114; P=0.010). However, the ADCS-ADL scale, which evaluates daily living activities, did not reach statistical significance at the 48-week mark.
In addition to the cognitive and functional measures, the secondary outcome data revealed notable improvements in the plasma Aβ42/40 ratio, an important biomarker in Alzheimer’s disease pathology, with the blarcamesine group showing a significant increase compared to placebo (P=0.048). MRI scans demonstrated a significant reduction in whole-brain volume loss in the blarcamesine group (P=0.002), suggesting that the drug may slow neurodegeneration in Alzheimer’s disease.
Safety and Tolerability
In terms of safety, the trial reported treatment-emergent adverse events (TEAEs) in 16.7% of participants in the blarcamesine group and 10.1% in the placebo group. Notably, the most common TEAE was dizziness, which was transient and mild to moderate in severity. Importantly, no neuroimaging adverse events were associated with the use of blarcamesine, underscoring its safety profile.
One of the most significant findings from the trial was the slowing of clinical progression in the blarcamesine-treated group. The results showed that blarcamesine slowed cognitive decline by 36.3% at 48 weeks, with similar effects observed in both the 30 mg (34.6% reduction) and 50 mg (38.5% reduction) dose groups. These findings were further supported by the drug’s effect on the SIGMAR1 receptor pathway, which was confirmed by a prespecified analysis of a genetic variant associated with the SIGMAR1 receptor.
Future Implications for Alzheimer’s Disease Treatment
Anavex Life Sciences’ blarcamesine represents a significant advancement in the search for effective treatments for Alzheimer’s disease. The fact that it is an oral Alzheimer’s disease medication sets it apart from many other treatments currently in development, particularly those that focus on anti-beta-amyloid therapies. Blarcamesine could provide a complementary or alternative approach to existing treatment strategies by addressing the neurodegenerative aspects of the disease through its unique mechanism of action—SIGMAR1 activation.
As the search for disease-modifying treatments for Alzheimer’s disease continues, the results from this trial position Anavex Life Sciences as a leader in the field. Blarcamesine’s ability to demonstrate statistically significant improvements in cognitive function, coupled with its safety profile, make it a strong candidate for further development and potential approval as an oral treatment option for early Alzheimer’s disease.
